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Abstract
Background: This study was carried out to detect human cytomegalovirus (HCMV) IgG and IgM antibodies using
an Enzyme-linked immunosorbent assay (ELISA) in renal transplant patients in Khartoum state, Sudan and to
improve the diagnosis of HCMV through the introduction of Real-time Polymerase Chain Reaction (PCR) testing. A
total of 98 plasma samples were collected randomly from renal transplant patients at Ibin Sina Hospital and Salma
Centre for Transplantation and Haemodialysis during the period from August to September 2006.
Results: Among the 98 renal transplant patients, 65 were males and 33 females. The results revealed that HCMV
IgG was present in all patients’ plasma 98/98 (100%), while only 6/98 (6.1%) had IgM antibodies in their plasma.
HCMV DNA viral loads were detected in 32 patients 32/98 (32.7%) using Real-time PCR.
Conclusions: The HCMV IgG results indicate a high prevalence of past HCMV infection in all tested groups, while
the finding of IgM may reflect a recent infection or reactivation. HCMV detection by real-time PCR in the present
study indicated a high prevalence among renal transplant patients in Khartoum. In conclusion, the prevalence of
HCMV in Khartoum State was documented through detection of HCMV-specific antibodies. Further study using
various diagnostic methods should be considered to determine the prevalence of HCMV disease at the national
level.
Background
Human cytomegalovirus (HCMV) is a member of the
Betaherpesvirinae subfamily which belongs to the family
Herpesviridae [1]. Betaherpesviruses,a l s oi n c l u d e s
human herpesvirus 6 (HHV-6) and human herpesvirus 7
(HHV-7), viruses that are more closely related to each
other than to other herpesviruses. HCMV is strictly spe-
cies specific, as are the other cytomegaloviruses. As with
all members of the family, the virus can persist in the
host in a latent state after primary infection [2]. It is a
ubiquitous virus, the seroprevalence of which reportedly
varies between 30 and 100% in different countries.
Transmission of HCMV can occur vertically or horizon-
tally via direct contact with infectious body fluids or
blood. The virus can also be transmitted by blood pro-
ducts or transplanted organs [2]. Although rarely
pathogenic in immunocompetent individuals, the virus
poses a significant health threat to immunocompro-
mised individuals, and is an important cause of morbid-
ity and mortality, especially in organ allograft and bone
marrow transplant patients [3]. When the host immune
system is compromised, either through infection- with
human immunodeficiency virus (HIV), immunity (neo-
nate), or through iatrogenic means following organ
transplantation, the virus is able to exert its full patho-
genic potential [2]. Many risk factors for the develop-
ment of HCMV symptomatic disease have been
suggested, and viral load is known to be a major indica-
tor for development of HCMV disease [2].
Diagnosis of HCMV disease is based on clinical symp-
toms, but the symptoms of HCMV can be confused
with those due to Epstein-Barr virus (EBV), and this
may lead to difficulties in diagnosis. Laboratory confir-
mation can be achieved using serological and molecular
techniques.
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related disease prevalence in the Sudan. Hence, the aim
of this research work was to generate preliminary infor-
mation about HCMV infection in renal transplant
patients and to establish and improve laboratory diagno-
sis of HCMV in Sudanese renal transplant patients.
Results
Detection of HCMV antibodies
HCMV IgG antibodies were present in the plasma sam-
ples of all patients tested, 65 (66.3%) males and 33
(33.7%) females. (Table 1). However, HCMV IgM anti-
bodies were demonstrable in plasma samples of only six
of the 98 patients (6.1%) tested. Of these positive
patients, 5 (5.1%) were males while only one (1.02%)
was a female (Table 1).
CMV Real-Time PCR
HCMV DNA was detected in 32/98 (32.7%) of the sam-
ples tested, with viral loads ranging from <200 to 42932
copies/mL. In terms of gender; 20 (20.4%) were males
while 12 (12.2%) were females.
Comparison of IgG and IgM ELISA with Real-Time PCR
results
The cross-tabulation between real-time PCR and ELISA
(IgM and IgG) is shown in (Table 2). A total of 32
patient samples exhibited both IgG by ELISA and DNA
by Real-time PCR. Likewise, IgM was detectable by
ELISA in plasma samples from two patients with DNA
concomitantly demonstrable by Real-time PCR. By com-
parison, IgG was detected in samples from 66 patients,
with no DNA detectable by Real-time PCR. Similarly,
IgM was present in four serum samples tested by
ELISA, but no DNA was detected by Real-time PCR.
Discussion
HCMV continue to be a significant cause of morbidity
and mortality in immunocompromised patients such as
organ or renal transplant recipients [4]. Effective pre-
emptive antiviral therapy like gancyclovir and foscarnet
depends on detecting HCMV disease at an early stage of
infection [5]. Rapid and accurate diagnosis of HCMV
infection is an essential part of such case management.
Moreover, the quantification of the systemic HCMV
load may provide a highly sensitive and specific method
to predict which patients will develop HCMV disease.
The present study has focused on the serologic and
molecular diagnosis of HCMV in renal transplant
patients in Khartoum State in the Sudan. The 100% pre-
valence of HCMV IgG antibodies found in this study
indicates a high rate of past infection, and demonstrates
t h a tH C M Vi n f e c t i o ni sc o m m o ni nS u d a n .T h i sh i g h
prevalence of HCMV may be attributed to the poor
socioeconomic status, poor living conditions, and hygie-
nic practices [6]. In contrast to IgG results, IgM antibo-
dies were detected in only 6.1% of the investigated
patients. This finding may reflect an active infection [7].
These findings might be considered alarming indicators
of disease in such patients.
T h ep r e v a l e n c eo fH C M Vi n f e c t i o ni nt h eg e n e r a l
population of African countries as well as in transplant
patients is reportedly high. The seroprevalence has been
reported to be 90% in Eritrea [8], 77.6% in Ghana [9],
and 36.2% in Egypt [10]. Our results parallel those
findings.
Serologic tests results in renal transplant patients can
be confused by blood transfusions and/or antibody-
based therapies. Furthermore, increases or decreases in
antibody levels, in general, do not necessarily support an
actual diagnosis of HCMV infection in the immunosup-
pressed patient populations, due to frequent reactivation
of the virus. Therefore, serology has limited diagnostic
value in the transplant patient group [11]. A Real-Time
PCR method was used in the present study as a highly
sensitive and specific method to predict which patients
will develop HCMV disease. HCMV by real-time PCR
was detected in 32/98 (32.7%) patients, a rate which was
clearly higher than the IgM result (6.1%). This might be
attributed to the fact that quantification of HCMV DNA
is considered both more sensitive and more specific
[12].
Table 1 Comparison between ELISA IgG and IgM for the
diagnosis of HCMV in plasma samples collected from
kidney transplant patients in Khartoum State, Sudan,
during the period from August to September, 2006
Gender Positive Negative Total tested
IgG Male 65 0 65
Female 33 0 33
IgM Male 5 60 65
Female 1 32 33
Table 2 Cross-tabulation between Real-time PCR and
ELISA (IgM and IgG) results for the diagnosis of HCMV in
plasma samples collected from kidney transplant
patients in Khartoum State, Sudan, during the period
from August to September, 2006
Real-time PCR
Positive Negative Total
ELISA IgG Positive 32 66 98
Negative 0 0 0
Total 32 66 98
IgM Positive 2 4 6
Negative 30 62 92
Total 32 66 98
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the current study, a function of the sensitivity and speci-
ficity of real-time PCR for detection of HCMV DNA as
compared to seroloic tests. However, the discrepancy
between the obtained negative results using IgM ELISA
with the corresponding positive results by real-time PCR
may be partially attributable to the time lag between pri-
mary infection and IgM antibody production since IgM
antibodies may remain undetectable because of delayed
seroconversion due to patient treatment with immuno-
suppressive agents [11]. HCMV DNA was not detected
in four patients who were IgM positive. This might be
due to the persistence of IgM antibodies for an extended
period of time after primary infection, as has been noted
in some healthy individuals [11].
In the present investigation, six patients displayed a
high viral load (mean value 17532.83 copies/ml) which
closely correlated with their clinical status suggestive of
active HCMV infection. Two of these patients died
within one year. Our results are in agreement with that
of Vincent et. al [13] who reported that HCMV load in
the initial phase of active infection as well as the rate of
increase in viral load both correlate with HCMV disease
in transplant recipients. The balance of the patients (26)
who had lower viral loads (mean value 23.076 copies/
ml) were asymptomatic.
Conclusions
This study was geared to serve as a baseline data analy-
sis for future studies, with a long term goal of introdu-
cing preemptive (anti-viral drugs) therapy against
HCMV in the Sudan. However, further research work
should be carried out to study the epidemiology and to
characterize HCMV at the molecular level.
Methods
Study population, data and biosample collection
Renal transplant recipients, who were not treated with
antiviral therapy, were recruited into this study. These
participants were recruited through the Ibin Sina Hospi-
tal and Dr. Salma Center for Transplantation and Hae-
modialysis, Khartoum State, between August and
September of 2006. All patients in this study presented
to the clinics suffering from a variable spectrum of com-
plaints; i.e., fever, diarrhea, hepatitis, neutropenia and/or
thrombocytopenia. Most of the patients presented 2-3
months after kidney transplantation. Case status and
clinical information was abstracted by reviewing medical
records. The collected data included age, gender, date of
transplantation, date of sample collection, and patient
location during sample collection. IRB approval for this
study was obtained by the Ibin Sina Hospital, Khartoum,
Sudan.
A total of 98 blood samples were collected from the
patients. Plasma was separated by centrifugation and
stored frozen at -20°C until further analyses. Plasma
samples were labeled with a unique non-identifying
code and express-shipped to New York for CMV DNA
analyses.
Serology and CMV Real-Time PCR analyses
Commercial ELISA kits (Biokit, Barcelona, Spain) were
used to detect HCMV IgG and IgM antibodies accord-
ing to the procedure described by the manufacturer.
For CMV testing, DNA was extracted from 200 μLo f
plasma using the QIAamp DNA Extraction kit (QIA-
GEN, Germantown, MD, USA). For each plasma sample,
5.5 μL (1 mg/mL) Carrier RNA and 10 μLC M Vi n t e r -
nal control were added to 200 μL of AL lysis buffer fol-
lowing the manufacturer’s recommendations. The
sample was eluted in 50 μL and 20 μL were used for the
assay. CMV viral load testing was carried out using the
artus CMV PCR assay according to the manufacturer’s
instructions (QIAGEN). The artus CMV™ Master Mix
contains reagents and enzymes for the specific amplifi-
cation of a 105-bp region of the major immediate early
antigen. A standard curve was obtained from the quanti-
tation standard (QS) CMV DNA positive controls (CMV
TM QS 1-4) provided by the manufacturer. For the PCR
amplification, 20 μL of DNA sample eluate was added to
30 μL of the working master mix. The amplicons were
then detected by measuring fluorescence, using the ABI
PRISM
® 7900HT Sequence Detection System (Applied
Biosystems, Carlsbad CA, USA) with the following
amplification conditions: 95°C for 10 min, followed by
45 cycles of 95°C for 15 sec and 55°C for 1 min. At the
e n do ft h er u n ,t h ed a t aw e r ea n a l y z e du s i n gt h eS D S
detection software v2.2.2 (ABI). The linear range of the
CMV DNA test was from 2.3 to 5.7 log10 copies/mL.
Quantitative results were reported if >2.3 log10 copies/
mL (200 copies/mL); positive results below 2.3 log10
copies/mL were reported as <200 copies/mL, CMV
DNA detected.
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